Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ
$2.99
▼ DOWN 4.47% (-0.14)

KEY STATISTICS

Market Cap$277.09 M
52w High$10.40
52w Low$2.25
Dividend Yield—
Frequency—
P/E-18.85
Volume893.29K
Shares Out.92.67M

COMPANY

LEADERSHIP

Terrie Kellmeyer
CHIEF EXECUTIVE
Terrie Kellmeyer

COMPENSATION 2026

Salary$700,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$16,100
Total$2,783,700

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 2, 2006
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
34

PRICE TARGET

Target High$11.00
Target Low$11.00
Target Median$11.00
Target Consensus$11.00

UPCOMING EARNINGS

DateNov 24, 2026
DayTuesday
Rev. Est.—
NOV
24
TUE

SPLIT RECORD

DATETYPERATIO
2015-10-07Reverse1:4

PRICE

$2.99 ▼ DOWN 4.47% (−$0.14)
OVERLAYS
$2.95$3.00$3.05$3.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.99

About Anavex Life Sciences Corp.

https://www.anavex.com ↗

Anavex Life Sciences develops drug candidates, including ANAVEX 2-73 and ANAVEX 3-71, for CNS diseases like Alzheimer's, Parkinson's, Rett syndrome, and neurodegenerative disorders, with several in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT ANAVEX LIFE SCIENCES CORP. IS KNOWN FOR

Blarcamesine (ANAVEX®2-73)
Blarcamesine (ANAVEX®2-73)

Blarcamesine is Anavex's lead investigational oral drug for neurodegenerative and neurodevelopmental disorders, having completed late-stage trials for Alzheimer's, Rett syndrome, and Parkinson's disease dementia.

COMPETITORS

COMPETITOR
ACAD COMPARE
ANVS COMPARE
BIIB COMPARE
LLY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
78
LISTED HERE
14
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.9M
IWM
0.01% · 2.4M
SCHA
0.01% · 436.3K
R2SC.L
0.01% · 220.7K
SBIO
0.14% · 114.7K
XRS2.DE
0.01% · 74.3K
PRFZ
0.01% · 56.8K
RSSL
0.01% · 43.8K
ASD
2.85% · 13.2K
DFAC
0.00% · 4.7K
URTY
0.00% · 3.7K
VETS
0.02% · 2.2K
AVSC
0.00% · 465
RESM
0.01% · 176

INSTITUTIONAL OWNERSHIP

SHARES OWNED
38.80%
HOLDERS
277
TOP 12 OF 277 · RANKED BY POSITION SIZE
Blackrock, Inc.
8.1M sh · $20.86M
Blackrock Inc.
6.4M sh · $26.97M
Vanguard Group Inc
5.1M sh · $45.43M
State Street Corp
4.5M sh · $13.85M
Two Sigma Investments, LP
3.2M sh · $9.97M
Geode Capital Management, LLC
2.4M sh · $6.24M
Two Sigma Advisers, LP
1.2M sh · $4.31M
Federated Hermes, Inc.
1.1M sh · $2.78M
Blackrock Fund Advisors
1.1M sh · $4.19M
Susquehanna International Group, Llp
995.7K sh · $3.06M
Aqr Capital Management LLC
963.0K sh · $2.49M
Summit Financial, LLC
940.5K sh · $2.89M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2022-12-12
 Christopher L. Jacobs
Christopher L. Jacobs
Sale (Full)
2022-12-12

INSIDER TRADES

★
OFFICER: INTERIM CEO
Kellmeyer Terrie
— · 46.7K shares
2026-05-04
★
OFFICER: INTERIM CEO
Kellmeyer Terrie
— · 7.5K shares
2026-05-04
★
OFFICER: INTERIM CEO
Kellmeyer Terrie
— · 50.0K shares
2026-05-04
★
DIRECTOR:
Paeger Axel
— · —
2026-02-23

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
HOLD 1
3 GRADES IN THE LAST 12 MONTHS
D. Boral Capital BUY HC Wainwright & Co. BUY Jones Trading HOLD

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
MBX$63.00COMPARE
ABSI$8.71COMPARE
MGTX$13.82COMPARE
MLTX$14.99COMPARE
CTMX$3.21COMPARE
VALN$6.43COMPARE
ARVN$9.18COMPARE